J Korean Diabetes.  2011 Sep;12(3):171-173. 10.4093/jkd.2011.12.3.171.

A Case of Gabapentin-induced Myoclonus in a Type 2 Diabetic Patient with End-stage Renal Disease

• Choe EY
• Lee BW
• Park KH
• Seok H
• Kim D
• Kang ES
• Cha BS
• Lee HC

• KMID: 2059845
• DOI: http://doi.org/10.4093/jkd.2011.12.3.171

Abstract

Development of myoclonus can manifest as a side effect of antiepileptic drugs in subjects with preexisting epilepsy, post-traumatic brain injury, encephalopathy, or focal and multifocal brain lesions. A 69-year-old male showed new onset severe myoclonus and confusion two days after taking 1200 mg gabapentin. The patient had end-stage renal disease secondary to type 2 diabetes and was receiving hemodialysis twice a week. After increasing hemodialysis to three times a week and discontinuing gabapentin, myoclonus spontaneously resolved. Here we report the first case of myoclonus in a Korean subject with diabetic renal failure. We recommend caution in the administration of gabapentin for diabetic subjects with renal disease.

Keyword

Gabapentin; Myoclonus; Diabetic neuropathies; Chronic renal failure

MeSH Terms

Aged
Amines
Anticonvulsants
Brain
Brain Injuries
Cyclohexanecarboxylic Acids
Diabetic Neuropathies
Epilepsy, Post-Traumatic
gamma-Aminobutyric Acid
Humans
Kidney Failure, Chronic
Male
Myoclonus
Renal Dialysis
Renal Insufficiency
Amines
Anticonvulsants
Cyclohexanecarboxylic Acids
gamma-Aminobutyric Acid

Reference

1. Scullin P, Sheahan P, Sheila K. Myoclonic jerks associated with gabapentin. Palliat Med. 2003; 17:717–8.

2. Healy DG, Ingle GT, Brown P. Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure. Mov Disord. 2009; 24:2028–9.

3. Asconapé J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia. 2000; 41:479–81.

4. Zhang C, Glenn DG, Bell WL, O'Donovan CA. Gabapentin-induced myoclonus in end-stage renal disease. Epilepsia. 2005; 46:156–8.

5. Han SW, Kim SY, Chu MK, Yu KH, Kim YJ, Lee BC, Kim J. Gabapentin-induced myoclonus in a patient with end-stage renal disease. J Korean Neurol Assoc. 2006; 24:495–7.

6. Cho KT, Hong SK. Myoclonus induced by the use of gabapentin. J Korean Neurosurg Soc. 2008; 43:237–8.

7. Mercadante S, Villari P, Fulfaro F. Gabapentin for opiod-related myoclonus in cancer patients. Support Care Cancer. 2001; 9:205–6.

8. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia. 2001; 42:790–2.

9. Pranzatelli MR. Serotonin and human myoclonus. Rationale for the use of serotonin receptor agonists and antagonists. Arch Neurol. 1994; 51:605–17.

10. Suzuki R, Rahman W, Rygh LJ, Webber M, Hunt SP, Dickenson AH. Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. Pain. 2005; 117:292–303.

11. Rao ML, Clarenbach P, Vahlensieck M, Kr?tzschmar S. Gabapentin augments whole blood serotonin in healthy young men. J Neural Transm. 1988; 73:129–34.

12. Pappert EJ, Goetz CG, Stebbins GT, Belden M, Carvey PM. 5-Hydroxytryptophan-induced myoclonus in guinea pigs: mediation through 5-HT1/2 receptor subtypes. Eur J Pharmacol. 1998; 347:51–6.

13. Welsh JP, Placantonakis DG, Warsetsky SI, Marquez RG, Bernstein L, Aicher SA. The serotonin hypothesis of myoclonus from the perspective of neuronal rhythmicity. Adv Neurol. 2002; 89:307–29.

14. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006; 81(4 Suppl):S3–11.

15. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004; 27:1458–86.

16. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998; 280:1831–6.

17. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003; 25:81–104.